SLC39A1 and prostate carcinoma: This suggests that the efficacy of the drugs that inhibit promoter hypermethylation, like 5-azacytidine, observed in prostate cancer cells, can be due to the reactivation of genes involved in cancer cell metabolism like hZIP1 and hZIP3.